[Clinical course of recurrent and metastatic disease in breast cancer].
Medical records of 434 patients with stage I, II and III breast cancer and a minimum follow up of 5 years were reviewed. Patients with distant metastasis and failure of regional therapy were identified. 94 of 434 patients treated developed failure. Median time for regional failure in stages I and II was 2.5 years, and 3 years for development of distant metastasis. Bone metastasis developed later than elsewhere in all states. Metastasis were observed before 5 years of follow up in all cases who developed this complication. Survival for patients with regional recurrence was 65% at 5 years, while survival for patients with metastasis was less than 20% in the same period. After development of metastasis, survival was no different according to initial stage of the tumor. We conclude that patients with breast cancer and regional recurrence have a reasonably good prognosis. This worsens drastically if distant metastasis develop.
Koffmann
B
B
Unidad de Cirurgía, Hospital Paula Jaraquemada, Santiago de Chile.
Baez
M R
MR
D000206:Actuarial Analysis; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors
Evolución de la enfermedad metastasica y recidivante en cáncer de mama.